The European biotechnology sector continues to experience a subdued atmosphere, echoing the overall morosity that dominated most of 2025. As the first quarter of 2026 unfolds, the anticipated resurgence in deal activity has yet to materialise, with no European biotechnology company involved in a major transaction in this first period